Biology and treatment of myelodysplastic syndromes--developments in the past decade (Q40895768)

24 September 2017

1 reference

title

Biology and treatment of myelodysplastic syndromes--developments in the past decade (English)

1 reference

24 September 2017

R Willemze

1 reference

24 September 2017

W E Fibbe

1 reference

24 September 2017

J H Falkenburg

1 reference

24 September 2017

J C Kluin-Nelemans

1 reference

24 September 2017

P M Kluin

1 reference

24 September 2017

J E Landegent

1 reference

24 September 2017

language of work or name

1 reference

1 March 1993

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

1 reference

24 September 2017

page(s)

107-115

1 reference

Proposals for the classification of the myelodysplastic syndromes

24 September 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01697618

Treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor. A phase I-II trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FBF01697618

Phase I study of recombinant human interleukin-3 in patients with bone marrow failure

21 January 2018

1 reference

12 December 2020

The 5a-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands

1 reference

12 December 2020

Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders

1 reference

12 December 2020

Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin

1 reference

12 December 2020

Recombinant human erythropoietin in patients with myelodysplastic syndromes

1 reference

12 December 2020

Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors

1 reference

12 December 2020

Effects of recombinant human interleukin-3 in patients with myelodysplastic syndromes

1 reference

12 December 2020

Chromosomal deletions in the myelodysplastic syndrome

1 reference

12 December 2020

In vitro growth pattern and differentiation predict for progression of myelodysplastic syndromes to acute nonlymphocytic leukaemia

1 reference

12 December 2020

Impact of marrow cytogenetics and morphology on in vitro hematopoiesis in the myelodysplastic syndromes: comparison between recombinant human granulocyte colony-stimulating factor (CSF) and granulocyte-monocyte CSF

1 reference

12 December 2020

Order of human hematopoietic growth factor and receptor genes on the long arm of chromosome 5, as determined by fluorescence in situ hybridization

1 reference

12 December 2020

Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome with excess blasts

1 reference

12 December 2020

Chromosome abnormalities in the myelodysplastic syndromes.

1 reference

12 December 2020

Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome

1 reference

12 December 2020

Phase I/II study of recombinant human granulocyte-macrophage colony-stimulating factor in aplastic anemia and myelodysplastic syndrome

1 reference

12 December 2020

Update on the prognostic implication of morphology, histology, and karyotype in primary myelodysplastic syndromes

1 reference

12 December 2020

Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: a clinical and erythrokinetic assessment

1 reference

12 December 2020

Myeloid but not lymphoid cells carry the 5q deletion: polymerase chain reaction analysis of loss of heterozygosity using mini-repeat sequences on highly purified cell fractions

1 reference

12 December 2020

1 reference

12 December 2020

Subcutaneous granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndrome: toxicity, pharmacokinetics, and hematological effects

1 reference

12 December 2020

Clonal involvement of granulocytes and monocytes, but not of T and B lymphocytes and natural killer cells in patients with myelodysplasia: analysis by X-linked restriction fragment length polymorphisms and polymerase chain reaction of the phosphogly

1 reference

12 December 2020

Treatment of myelodysplastic syndromes with recombinant human erythropoietin.

1 reference

12 December 2020

Clonality in myeloproliferative disorders: analysis by means of the polymerase chain reaction

1 reference

12 December 2020

A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome

1 reference

12 December 2020

Comparison of intravenous versus subcutaneous recombinant human granulocyte-macrophage colony-stimulating factor in patients with primary myelodysplasia

1 reference

12 December 2020

Recommendations for a morphologic, immunologic, and cytogenetic (MIC) working classification of the primary and therapy-related myelodysplastic disorders. Report of the workshop held in Scottsdale, Arizona, USA, on February 23-25, 1987. Third MIC Co

1 reference

12 December 2020

Myelodysplastic syndromes: natural history and features of prognostic importance

1 reference

12 December 2020

Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial

1 reference

12 December 2020

Myelodysplastic syndromes: a scoring system with prognostic significance

1 reference

12 December 2020

In vivo effects of granulocyte-macrophage colony-stimulating factor and interleukin-3 on clonal and non-clonal cell populations in patients with clonal hematopoietic disorders

1 reference

12 December 2020

Chronic and subacute myelomonocytic leukaemia in the adult: a report of 60 cases with special reference to prognostic factors

1 reference

12 December 2020

Studies on clonality by PCR analysis of the PGK-1 gene

1 reference

12 December 2020

Clonal karyotype abnormalities and clinical progress in the myelodysplastic syndrome

1 reference

12 December 2020

Clonal analysis of myelodysplastic syndrome: monosomy 7 is expressed in the myeloid lineage, but not in the lymphoid lineage as detected by fluorescent in situ hybridization

1 reference

12 December 2020

Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells

1 reference

12 December 2020

Danazol treatment of myelodysplastic syndromes

1 reference

12 December 2020

In vivo administration of granulocyte-macrophage colony stimulating factor enhances neutrophil function in patients with myelodysplastic syndromes

1 reference

12 December 2020

Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears

1 reference

12 December 2020

Treatment of advanced myelodysplastic syndromes with recombinant interferon-alpha 2b

1 reference

12 December 2020

Effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes

1 reference

12 December 2020

Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients

1 reference

12 December 2020

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system

1 reference

12 December 2020

Correlation of bone marrow colony growth in the myelodysplastic syndromes with the FAB classification and the Bournemouth score

1 reference

12 December 2020

Myelodysplastic syndromes

1 reference

12 December 2020

Disappearance of cytogenetic abnormalities and clinical remission during therapy with 13-cis-retinoic acid in a patient with myelodysplastic syndrome: inhibition of growth of the patient's malignant monocytoid clone

1 reference

12 December 2020

Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.

1 reference

12 December 2020

High-dose recombinant human erythropoietin for treatment of anemia in myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria: a pilot study

1 reference

12 December 2020

RAS mutations in myelodysplasia detected by amplification, oligonucleotide hybridization, and transformation.

1 reference

12 December 2020

Effect of treatment with rhGM-CSF and low-dose cytosine arabinoside on leukemic blast cells in patients with myelodysplastic syndromes

1 reference

12 December 2020

Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor

1 reference

12 December 2020

Clonality of cell populations in refractory anaemia using combined approach of gene loss and X-linked restriction fragment length polymorphism-methylation analyses

1 reference

12 December 2020

Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes

1 reference

12 December 2020

Effect of subcutaneously administered human recombinant erythropoietin on erythropoiesis in patients with myelodysplasia

1 reference

12 December 2020

Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes

1 reference

12 December 2020

Erythropoietin treatment in patients with myelodysplastic syndrome and anemia

1 reference

12 December 2020

Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes.

1 reference

12 December 2020

Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes

1 reference

12 December 2020

Combined immunophenotyping and DNA in situ hybridization to study lineage involvement in patients with myelodysplastic syndromes

1 reference

12 December 2020

Kit ligand improves in vitro erythropoiesis in myelodysplastic syndrome

1 reference

12 December 2020

A phase II trial of recombinant human granulocyte colony-stimulating factor in the myelodysplastic syndromes

1 reference

12 December 2020

The treatment of anaemia in the myelodysplastic syndromes with recombinant human erythropoietin

1 reference

12 December 2020

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

12 December 2020

Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders

1 reference

12 December 2020

Stimulation of nonclonal hematopoiesis and suppression of the neoplastic clone after treatment with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with therapy-related myelodysplastic syndrome

1 reference

12 December 2020

Recombinant human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes--a phase I/II trial

1 reference

12 December 2020

Refined chromosome analysis as an independent prognostic indicator in de novo myelodysplastic syndromes

1 reference

12 December 2020

A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

1 reference

12 December 2020

The combined effects of Il-3, GM-CSF and G-CSF on the in vitro growth of myelodysplastic myeloid progenitor cells

1 reference

12 December 2020

Clonal lymphocytes are detectable in only some cases of MDS

1 reference

12 December 2020

Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7

1 reference

12 December 2020

Utility of the FAB classification for myelodysplastic syndromes: investigation of prognostic factors in 237 cases

1 reference

12 December 2020

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF01697618

1 reference

24 September 2017

1 reference